Search Results - Internal medicine

Relation: We thank all cohort members and researchers who participated in the 31-year study of the Northern Finland Birth Cohort 1966. We also wish to acknowledge the work of the Northern Finland Birth Cohort project centre. The authors acknowledge the contributors of the data used in this work: CARDIoGRAMplusC4D, CHARGE, DIAGRAM, GIANT, GLGC, MAGIC, MEGASTROKE, and UK Biobank.; Karhunen , V , Gill , D , Huang , J , Bouras , E , Malik , R , Ponsford , M J , Ahola-Olli , A , Papadopoulou , A , Palaniswamy , S , Sebert , S , Wielscher , M , Auvinen , J , Veijola , J , Herzig , K-H , Timonen , M , Keinaenen-Kiukaanniemi , S , Dichgans , M , Salmi , M , Jalkanen , S , Lehtimaeki , T , Salomaa , V , Raitakari , O , Jones , S A , Hovingh , G K , Tsilidis , K K , Jaervelin , M-R & Dehghan , A 2023 , ' The interplay between inflammatory cytokines and cardiometabolic disease : bi-directional mendelian randomisation study ' , BMJ MEDICINE , vol. 2 , no. 1 , e000157 . https://doi.org/10.1136/bmjmed-2022-000157; http://hdl.handle.net/10138/573602; 36550082-82bb-4427-8a0d-72944ecd535f; 001150782000025

Availability: http://hdl.handle.net/10138/573602

5

Academic Journal

GWAS meta-analysis of over 29,000 people with epilepsy identifies 26 risk loci and subtype-specific genetic architecture

Authors: International League Against Epilepsy Consortium on Complex Epilepsies, Stevelink, Remi, Campbell, Ciarán, Daly, Mark J., Kurki, Mitja I., Neale, Benjamin M., Palotie, Aarno, Heyne, Henrike O., Eriksson, Johan G., Kälviäinen, Reetta, Kantanen, Anne-Mari, Saarela, Anni, Timonen, Oskari, Lehesjoki, Anna-Elina, Linnankivi, Tarja

Contributors: Institute for Molecular Medicine Finland, Centre of Excellence in Complex Disease Genetics, Research Programs Unit, Aarno Palotie / Principal Investigator, Genomics of Neurological and Neuropsychiatric Disorders, Clinicum, Johan Eriksson / Principal Investigator, Department of General Practice and Primary Health Care, Department of Medical and Clinical Genetics, Helsinki University Hospital Area, HUS Children and Adolescents

Subject Terms: 1184 Genetics, developmental biology, physiology, 3111 Biomedicine, 3112 Neurosciences, 3142 Public health care science, environmental and occupational health, 3121 General medicine, internal medicine and other clinical medicine

File Description: application/pdf

Relation: This study received support from Science Foundation Ireland (SFI; 16/RC/3948), cofunded under the European Regional Development Fund, the Research Unit FOR-2715 of the German Research Foundation (MN: NO755/6-1 and NO755/13-1), from Wellcome Trust (grant 084730), European Union’s Seventh Framework Program (FP7/2007-2013) under grant agreement 279062 (EpiPGX), The Muir Maxwell Trust and the Epilepsy Society, UK and Fonds National de la Recherche Luxembourg (Research Unit FOR-2715, FNR grant INTER/DFG/21/16394868 MechEPI2) to P.M. and R. Krause. Part of this work was undertaken at University College London Hospitals, which received a proportion of funding from the NIHR Biomedical Research Centers funding scheme. Further support was received by a ‘Vrienden WKZ’ fund 1616091 (MING) to R. Stevelink and B.P.C.K., a National Health and Medical Research Council (NHMRC) of Australia Program Grant (1091593) to S.F.B. and I.E.S. and an NHMRC Investigator grant (APP1195236) to M.B. The Australian Government Research Training Program Scholarship (APP533086) provided by the Australian Commonwealth Government and the University of Melbourne supports K.L.O., a Wellcome Clinical Ph.D. Fellowship on the 4Ward North program (203914/Z/16/Z) supported D.L.-S., the UKRI MRC award MR/S02638X/1 and the NIHR Imperial Biomedical Research Center (BRC) support M.R.J., and Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), Brazil (grant 2013/07559-3) supported I.L.-C. The funding bodies had no role in the study design, data collection, analysis and interpretation, or in writing the manuscript. We thank the Epi25 principal investigators, local staff from individual cohorts and all patients with epilepsy who participated in research studies at local centers for making possible this global collaboration and resource to advance epilepsy genetics research. This work is part of the Centers for Common Disease Genomics (CCDG) program, funded by the National Human Genome Research Institute (NHGRI), The Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Heart, Lung and Blood Institute (NHLBI). CCDG-funded Epi25 research activities at the Broad Institute, including genomic data generation in the Broad Genomics Platform, were supported by NHGRI grant UM1 HG008895 (PIs: E. Lander, S. Gabriel, M. Daly, S. Kathiresan). The Genome Sequencing Program efforts were also supported by NHGRI under grant 5U01HG009088-02. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We thank the Stanley Center for Psychiatric Research at the Broad Institute for supporting the genomic data generation efforts as well as the aggregation of control samples and cohorts to contribute to the Epi25 GWAS analyses. In particular, the Genomic Psychiatry Cohort controls were genotyped on the GSA-MD v1.0 by the Broad Genomics Platform with funding from NIH grant U01MH105641 and the Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard. The FINRISK controls were part of the FINRISK studies supported by the THL (formerly KTL: National Public Health Institute) through budgetary funds from the government, with additional funding from institutions such as the Academy of Finland, the European Union, ministries and national and international foundations and societies to support specific research purposes. The collection of the Hong Kong Osteoporosis Study (HKOS) control samples was funded by the Bone Health Fund and Research Grants Council—Early Career Scheme (project 27100416). Other control datasets included IBD NIDDK and samples from the Mass General Brigham (MGB) Biobank available from dbGaP under study accession number phs002018.v1.p1. G.L.C. is in receipt of research funding from Congenica and Janssen Pharmaceuticals and has conducted consultancy for Ono Pharmaceuticals. S.F.B. received funding from UCB Pharma and Eisai and has been a consultant for Praxis Precision Medicines and Sequiris. Q.S.L. is an employee of Janssen Research & Development, LLC and a shareholder in Johnson & Johnson, which is the parent company of the Janssen companies. B.M.N. currently serves as a member of the scientific advisory board at Deep Genomics and Neumora (previously RBNC) and as a consultant for Camp4 Therapeutics. S.P. is an employee and shareholder of AstraZeneca. U.U., S.M., H. Stefansson and K.S. are employees of deCODE genetics/Amgen.; International League Against Epilepsy Consortium on Complex Epilepsies , Stevelink , R , Campbell , C , Daly , M J , Kurki , M I , Neale , B M , Palotie , A , Heyne , H O , Eriksson , J G , Kälviäinen , R , Kantanen , A-M , Saarela , A , Timonen , O , Lehesjoki , A-E & Linnankivi , T 2023 , ' GWAS meta-analysis of over 29,000 people with epilepsy identifies 26 risk loci and subtype-specific genetic architecture ' , Nature Genetics , vol. 55 , no. 9 , pp. 1471-1482 . https://doi.org/10.1038/s41588-023-01485-w; ORCID: /0000-0002-2527-5874/work/154009783; http://hdl.handle.net/10138/571721; f9a2f528-3f1c-41c8-b763-3e74c452709d; 85169457451; 001169861400003

Availability: http://hdl.handle.net/10138/571721